Introduction
Heart failure (HF) affects 2% of the Western population.
1 Despite pharmacological therapy, cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICD), HF is the most common cause of hospitalization 2 and is associated with poor quality of life and an overall 1-year mortality of over 20%. 3, 4 Heart transplantation (HTx) and left ventricular assist devices or systems (LVASs) for bridge to transplant (BTT) or destination therapy (DT) improve symptoms and survival in advanced HF, 5 -8 with 1-year survival with either approaching 80-90%. 6, 7, 9, 10 However, patients with advanced HF may be underserved by HTx and LVAS. 1, 5, 7 A recent single-centre pilot study suggested that there are many patients with unrecognized need for HTx and/or LVAS.
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The main reason for not offering or considering HTx is persisting donor organ shortage. 5 The reasons for low LVAS use are unknown but may relate to poor awareness, inefficient organization of advanced HF care, or financial constraints. Furthermore, there is consensus that patients are often referred too late for HTx and LVAS evaluation, implying that HTx and LVAS will carry higher risk or be contraindicated. 9, 10 We hypothesized that (i) HF patients are under-referred for HTx and LVAS, (ii) screening patients with CRT/ICD can identify appropriate HTx/LVAS candidates, and (iii) identified candidates will accept offered interventions.
Methods

Study design and oversight
The ScrEEning for advanced Heart Failure treatment (SEE-HF) study (ClinicalTrials.gov identifier NCT01626404) was a multicentre, multinational, single-arm, open-label, phase 4 interventional screening study (see Supplementary material online Appendix S1 for study protocol). The study was designed and overseen by the executive committee together with the sponsor (Thoratec Europe, Huntingdon, UK). Data were collected and analysed according to the pre-specified statistical analysis plan. To ensure broad representation of patients, we selected eight European centres from seven countries for participation in the study.
Patients
The inclusion criterion for screening for HTx and LVAS was CRT and/or ICD in place for any indication. These ambulatory patients were screened by chart review by dedicated study nurses or local investigators in outpatient clinics and from local rosters of patients. The inclusion criteria for more detailed assessment of HTx/LVAS candidacy were New York Heart Association (NYHA) class III-IV HF symptoms, ejection fraction (EF) ≤40% and stable optimal medical management (see Supplementary material online, Table S1 ).
Intervention
The intervention was a stepwise screening process. Table S2 ). Patients who met eligibility criteria for HTx or LVAS were offered listing for HTx or LVAS implantation. There was no randomization, blinding, or control group.
Pre-specified study outcomes
The primary outcome was defined as indication without contraindication for HTx or LVAS at the time of screening. Eligibility by guidelines was determined by the principal investigator at each site. Secondary outcomes included presence of indication without contraindication for (i) HTx and (ii) LVAS, and actual (iii) listing for HTx, and (iv) LVAS implantation, and (v) clinical outcomes up to 6 and 12 months after inclusion.
Statistics
The sample size was based on an assumption that among patients with NYHA class III-IV HF, LVEF ≤40%, and a CRT plus defibrillator (CRT/D) device, the number of patients who have an indication without contraindication for HTx or LVAS is between 7% and 13% (10 ± 3%). Based on these assumptions, 384 patients were required to obtain 95% confidence for these figures. However, it was pre-specified in the protocol that the steering committee could decide to stop inclusion after 100 patients if enrollment rate was found to be too slow, accepting that the desired power would then not be met. Data are presented as means (± standard deviation) or proportions, as appropriate. Differences between screened and enrolled patients were tested using Student's t-tests or chi-square test, as appropriate. Significance testing was not performed between individual groups of the enrolled patients due to low numbers and risk of a type II error.
Ethics
The study was approved by the ethics committee at each site and permitted screening as described. Patients identified as potential candidates in screening and who underwent further detailed assessment for HTx/LVAS eligibility provided written informed consent. 21 ) and left ventricular assist system (LVAS) (creatinine >3.5 mg/dL according to the HeartMate II destination therapy trial 30 ). BMI, body mass index; eGFR, estimated glomerular filtration rate; RV, right ventricular.
Patients and outcomes
Screened patients
Of 1722 screened patients (mean age 64 ± 14 years, 26% female), 121 (7.0%) were eligible, and 99 (5.7%) consented to further assessment. Figure 1 criteria, 167 (9.7%; range 0-13%) failed exclusion criteria, 217 (12%; range 1-85%) failed both, and 52 (3.0%; range 0-13%) had other reasons.
Characteristics of enrolled, eligible and treated patients
Among the screened patients, many lacked an indication for HTx or LVAS and, among those with an indication, several had contraindications. The prevalence of eligible candidates for HTx was 1.1% Tables 1 and 2 , divided into non-mutually exclusive groups: patients who lacked indication (n = 85, 86%), with contraindication for either or both (n = 28, 28%), eligible for either or both (n = 26, 26%), and listed for HTx or received LVAS (n = 12, 12%).
Patients who were eligible were of similar age (61 ± 8 years) and gender distribution (19% women) as the overall cohort, but those actually listed for HTx or implanted with LVAS were younger (56 ± 8 years) and fewer women (8%). Eligible patients had similar extent of co-morbidity as ineligible patients, except less chronic kidney disease, psychiatric history, smoking, stroke and cancer, and also had worse NYHA class and lower systolic blood pressure, EF and peak oxygen consumption. Additionally, treated patients had less cancer and diabetes ( Table 1) . Of the 26 patients with indication without contraindication for either HTx or LVAS (primary outcome), 13 received either intervention (0.8% of screened and 13% of enrolled) ( Figure 3 ): nine were listed for HTx per protocol and two were listed for HTx despite guideline-based contraindication, for a total of 11 listed (0.6% of screened and 11% of enrolled). Of the 26 patients, two received LVAS per protocol and one received BTT LVAS after being listed for HTx outside the protocol, for a total of three implantations (0.2% of screened and 3% of enrolled).
Eligible and especially treated patients had more severe HF as judged by lower body mass index, blood pressure, and EF, but lower risk for intervention as judged by better estimated glomerular filtration rate and bilirubin. Eligible and treated patients had worse NYHA class and especially worse INTERMACS class, with 45% of treated patients in INTERMACS 4. Peak oxygen consumption, minute ventilation to carbon dioxide output slope and 6-minute walk distance were also somewhat worse in eligible and especially treated patients ( Table 2) .
The inability to walk without aid, one city block, one flight of stairs, and with groceries, was overall similar among groups, ranging from 0% to 33%. The Patient Health Questionnaire-9 (PHQ-9) quality of life and symptoms of depressions were worse in patients with contraindications, but otherwise similar across groups.
. 
Follow-up
At 6 months, nine of the 26 patients (35%) who were eligible for HTx or LVAS at baseline had a change in status: three HTx, two elective LVASs, one death, one improved medically and was no longer a HTx candidate, and two patients who initially chose not to be listed were then listed for HTx. At 12 months post-enrollment, another patient who was eligible for HTx or LVAS at baseline underwent elective HTx and a second patient was temporarily removed as a transplant candidate. At 6 months, two patients who were not eligible for HTx or LVAS at baseline had expired, one withdrew consent and was not followed, one was lost to follow-up, and one received an urgent total artificial heart. Four additional patients remained not eligible but with worsening conditions, including one who experienced a stroke, one diagnosed with oesophageal cancer, and two with declines in their general health. At 12 months post-enrollment, three additional patients had expired, one received a HTx, two improved medically and were no longer considered for transplant or LVAS, and one patient was listed for HTx despite contraindications but expired before receiving a transplant.
Within 6 months, seven unplanned cardiovascular hospitalizations occurred in four of the 26 patients (15%) eligible for HTx or LVAS at baseline, and 17 cardiovascular hospitalizations occurred in 14 of the 73 non-eligible patients (19%).
Discussion
This is the first multicentre study of screening patients for potential HTx and LVAS eligibility. Our findings suggest that (i) formulaic or standardized screening based on the presence of CRT/ICD identifies eligible HTx/LVAS candidates with a low yield (only 1.5% were eligible for intervention, and 0.8% actually treated), but (ii) when NYHA class III-IV and reduced EF are considered, a large proportion of patients (26% in our study) have unrecognized guideline-based indication without contraindication for HTx or LVAS, and (iii) when these patients are offered therapy based on screening, only half accept.
Current referral pattern
Worldwide HTx is increasing slowly but remains a limited option for advanced HF. 10 The proportion of HTx worldwide bridged with LVAS has increased from <20% to ∼50%, 10 and the DT implant rate has increased 10-fold. 9 However, patients with advanced HF are still believed to be underserved by HTx and LVAS. 1, 5, 7 The 26% eligibility for HTx/LVAS among our enrolled patients confirms that there is substantial under-referral for HTx/LVAS. Our data also show that indications and contraindications change over time, as more than 30% of patients change status from being eligible to non-eligible or vice versa over 1 year.
Effect of screening
In adult medicine, screening is used primarily for cancer diagnoses and remains a controversial topic. To our knowledge, systematic screening has not yet been used or studied in the field of advanced HF. Importantly, our findings suggest that screening is justified according to the Wilson criteria ( Table 3) . 16 Which HF patients, if any, should be screened? CRT improves symptoms and survival 17 and is widely accepted in the cardiology community. However, only about two-thirds respond, 17 and systematic CRT optimization does not appear to improve response. 18 CRT/ICD clinical encounters often focus on device interrogation and neglect clinical status. Therefore, a CRT/ICD clinic seems a reasonable place to start. However, we found that screening all CRT/ICD patients may not meet the 'common' criterion, as only 5.7% of screened patients were enrolled, 1.5% met eligibility, and 0.8% were treated. Screened patients were less ill than those defined as having advanced HF. 19 The fact that the majority of patients followed in the CRT/ICD clinic do not have an indication for referral for HTx/LVAS evaluation is not surprising. Many patients followed in the CRT/ICD clinic do not have HF at all, as they are followed for primary arrhythmias or arrhythmias associated with milder forms of cardiomyopathy, for instance many patients with hypertrophic cardiomyopathy. Finally the majority of patients with CRT respond to resynchronization therapy and as such are not candidates for HTx/LVAS.
In contrast, by adding NYHA class III-IV and reduced EF criteria, 26% of patients were eligible and 13% treated. This suggests that markers of HF severity 20 are necessary to justify the 'common' criterion for screening and should be further evaluated. Most patients who receive HTx or LVAS are in NYHA class IV and inotrope-dependent, 9,10 but both HTx and LVAS are indicated also in ambulatory patients in NYHA class IIIB if other markers of poor prognosis are present. patients receive intermittent levosimendan, without being further evaluated for HTx or LVAS. 22 Our study suggests that a simple criterion such as NYHA class III-IV HF, with EF <40%, and a CRT/D device should alert electrophysiologists and other clinicians to refer patients to a HF clinic or specialist. Indeed, it suggests that closer collaboration of electrophysiologists with HF specialists is urgently needed to ensure that CRT/D patients with low EF and persistent moderate/severe HF symptoms are followed up by cardiologists with specialized focus on the potential need for advanced therapies such as HTx or LVAS. The potential lack of awareness among clinicians caring for patients with CRT/D is also analogous to generalists providing less of the other evidence-based HF interventions. 4, 23 Nevertheless, eligibility in stable patients may be elusive to detect clinically, as there were no major differences between patients lacking an indication, having a contraindication and being eligible. Applying the INTERMACS criteria enhanced the distinction between non-eligible and eligible patients in our study, but this tool is not commonly used in patients perceived to be stable. This may explain why a majority of patients actually receiving interventions are severely ill, with an increasing proportion of HTx being performed from LVAS, 10 and a majority of LVAS still being implanted in INTERMACS 1-3 9 patients (excluded from our study).
Patient acceptance
Among patients meeting the primary endpoint (eligibility), only 50% underwent actual listing for HTx or LVAS implantation. This is consistent with the 56% of 162 ambulatory advanced HF patients in the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) registry who stated they would definitely or probably want an LVAS. 24 In another survey, only half of the patients would consider an LVAS if they had a life expectancy <1 year or could walk <1 block. 25 Our study differs from these in that we assessed actual eligibility and interventions rather than survey patient preference. Many patients who initially decline change their mind as symptoms worsen, 26 when it is often too late. Patients consistently underestimate the severity of their prognosis, 27 and in the above survey, nearly all patients would accept an LVAS if they were too ill to get out of bed, 25 which may be too late due to for example peripheral organ or right ventricular failure. In the HTx/LVAS community, we are accustomed to patients being desperate for help when they come to us, but half apparently do not accept help if we come to them. The patients in our study all met published eligibility criteria, which in turn are based on extensive observational or trial data suggesting that their symptoms and prognosis would improve with intervention. Thus, there does not appear to be clinical and patient equipoise, but it appears that treatment decisions made by patients when an indication is proposed following a screening process are different from those made when the patients seek medical attention based on their own experience of symptoms, even if symptoms and physical findings are similar.
While the present study sheds some light on the proportion of a specific group of patients perceived as stable outpatients who may actually have an indication for HTx or LVAS, the study clearly does not determine the proportion of patients who should be treated with these therapies nor does it provide information on which of these modalities should be used. The decision to offer (or accept) HTx or LVAS or, instead, stay on medical therapy alone is complex and is based on a large number of medical as well as non-medical factors, including organ availability, social, financial and regulatory aspects. 28 For instance, LVAS as DT is still not approved in all countries in Europe.
Limitations
Our study identified indications and contraindications at single time-points whereas in reality these are variable over time. However, identification of patients at early stages is desirable, given the general under-and too late-referral. 6, 29 The main limitation was the low sample size resulting from early termination of inclusion due to slow recruiting. This precluded statistical comparisons of patient groups and any firm conclusions regarding, for example, why some eligible patients and not others accepted intervention which would have to be tested in a larger study. Although the study was a multicentre study including patients form several countries in Europe, it is important to recognize major differences between healthcare systems with respect to both follow-up of HF patients and access to and acceptance of use of advanced therapies such as HTx and LVAS. Hence, the results of the present study can only be extrapolated to healthcare systems similar to those where the patients were recruited.
Conclusions
This first of its kind screening study in HF suggests that few patients with CRT and/or ICD in an outpatient setting are appropriate candidates for advanced treatment. NYHA class is III-IV, then more than one-quarter are candidates. Although our data suggest that it may not be worthwhile to screen unselected patients with CRT/ICD for indication for HTx or LVAS, it may be feasible and justified to screen CRT/ICD patients who also have NYHA III-IV HF and EF ≤40%. Patients not in extremis may be reluctant to accept surgical interventions, but identifying indications may be a start to a more informative discussion between patients, relatives and the HF team.
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